bleedHD: a Tool for Assessment of Bleeding and Graftversus-Host Disease in Hemato-oncological Patients

被引：0
|
作者：
Egger, M. [1 ]
Halter, J. [2 ]
Infanti, L. [2 ,3 ]
Plattner, A. [4 ]
Schefer, S. [5 ]
Angerer, L. [5 ]
Kistler, J. [6 ]
Passweg, J. [2 ]
Buser, A. [1 ,2 ]
Holbro, A. [1 ,2 ]
机构：
[1] Swiss Red Cross, Blood Transfus Serv, Basel, Switzerland
[2] Univ Basel Hosp, Hematol, CH-4031 Basel, Switzerland
[3] Blood Transfus Ctr, Basel, Switzerland
[4] Swiss Red Cross, Basel, Switzerland
[5] Getunik AG, Zurich, Switzerland
[6] Kistler Web Act, Zurich, Switzerland
来源：
BONE MARROW TRANSPLANTATION | 2016年 / 51卷
关键词：
D O I：
暂无
中图分类号：
Q6 [生物物理学];
学科分类号：
071011 ;
摘要：
AB37
引用
收藏
页码：S579 / S580
页数：2
相关论文
共 50 条
  • [41] DETERMINANTS OF SURVIVAL OF HEMATO-ONCOLOGICAL PATIENTS IN THE ICU 2004-2008. THE LEIDEN EXPERIENCE
    Essen, E. H. R. V.
    Brunsveld-Reinders, A. H.
    Borne, P. A. V. D.
    Arbous, M. S.
    INTENSIVE CARE MEDICINE, 2009, 35 : 292 - 292
  • [42] The Profile of Microorganisms Responsible for Port-Related Bacteremia in Pediatric Hemato-Oncological Patients
    Gowin, Ewelina
    swiatek-Koscielna, Bogna
    Mankowski, Przemyslaw
    Januszkiewicz-Lewandowska, Danuta
    CANCER CONTROL, 2020, 27 (01)
  • [43] Fear of progression in parents of children with hemato-oncological diseases - assessment, correlates and integration in psychosocial care
    Clever, K.
    Schepper, F.
    Christiansen, H.
    Martini, J.
    ONCOLOGY RESEARCH AND TREATMENT, 2017, 40 : 280 - 280
  • [44] Impact of Premedication Prior to Platelet Transfusion on Platelet Increment Among Hemato-Oncological Patients
    Berger, Tamar
    Yahalom, Vered
    Giladi, Odil
    Kugler, Eithan
    Shochat, Tzippy
    Meirman, Victoria
    Gal, Ella
    Klebovsky, Tetyana
    Wolach, Ofir
    Yeshurun, Moshe
    Raanani, Pia
    Shargian, Liat
    Pasvolsky, Oren
    BLOOD, 2023, 142
  • [45] Procalcitonin: a useful discriminator between febrile conditions of different origin in hemato-oncological patients?
    S. Schüttrumpf
    L. Binder
    T. Hagemann
    D. Berkovic
    L. Trümper
    C. Binder
    Annals of Hematology, 2003, 82 : 98 - 103
  • [46] Procalcitonin:: a useful discriminator between febrile conditions of different origin in hemato-oncological patients?
    Schüttrumpf, S
    Binder, L
    Hagemann, T
    Berkovic, D
    Trümper, L
    Binder, C
    ANNALS OF HEMATOLOGY, 2003, 82 (02) : 98 - 103
  • [47] Incidence and risk factors of adverse events in pediatric hemato-oncological patients: A cohort study
    de Charry, M. Quintero
    Tovar-Cuevas, J. R.
    Leon, H.
    Ocampo, C. E.
    JOURNAL OF HEALTHCARE QUALITY RESEARCH, 2022, 37 (02) : 110 - 116
  • [48] Experience with click-lock system on central venous catheter in hemato-oncological patients
    Weijermans, PW
    Grundeken, K
    Stolwijk, G
    BONE MARROW TRANSPLANTATION, 1999, 23 : S255 - S255
  • [49] Self-perceived oral health in hemato-oncological patients and the relation to quality of life
    Laheij, Alexa M. G. A.
    Dillen, Linda M.
    Nur, Erfan
    Raber-Durlacher, Judith E.
    SUPPORTIVE CARE IN CANCER, 2024, 32 (10)
  • [50] BELUMOSUDIL AND RUXOLITINIB COMBINATION THERAPY FOR TREATMENT OF STEROID-REFRACTORY CHRONIC GRAFTVERSUS-HOST DISEASE
    Pusic, Iskra
    Minor, Chelsea
    Lee, Catherine
    Veeraputhiran, Muthu
    DiPersio, John F.
    BONE MARROW TRANSPLANTATION, 2023, 58 (SUPP1) : 321 - 322
12345